[1] HUNTER DJ, BIERMA-ZEINSTRA S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.
[2] HUNTER DJ, MARCH L, CHEW M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020;396(10264):1711-1712.
[3] FARNAGHI S, CRAWFORD R, XIAO Y, et al. Cholesterol metabolism in pathogenesis of osteoarthritis disease. Int J Rheum Dis. 2017;20(2):131-140.
[4] ZHAO L, HUANG J, FAN Y, et al. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Ann Rheum Dis. 2019;78(5):676-682.
[5] SELLAM J, COURTIES A, EYMARD F, et al. Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis. Joint Bone Spine. 2020;87(6):548-555.
[6] BI L, YI J, WU C, et al. Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China. Front Cardiovasc Med. 2022;9:839571.
[7] KOSKINAS KC, SIONTIS GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172-1180.
[8] FULCHER J, O’CONNELL R, VOYSEY M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-1405.
[9] KADAM UT, BLAGOJEVIC M, BELCHER J. Statin use and clinical osteoarthritis in the general population: a longitudinal study. J Gen Intern Med. 2013;28(7):943-949.
[10] CHENG YY, KAO CL, LIN SY, et al. Effect of an increased dosage of statins on spinal degenerative joint disease: a retrospective cohort study. BMJ Open. 2018;8(2):e017442.
[11] WANG J, DONG J, YANG J, et al. Association between statin use and incidence or progression of osteoarthritis: meta-analysis of observational studies. Osteoarthritis Cartilage. 2020;28(9):1170-1179.
[12] MANSI IA, MORTENSEN EM, PUGH MJ, et al. Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis. Am J Med Sci. 2013;345(5):343-348.
[13] HEMANI G, ZHENG J, ELSWORTH B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
[14] EMDIN CA, KHERA AV, KATHIRESAN S. Mendelian Randomization. JAMA. 2017; 318(19):1925-1926.
[15] HARTWIG FP, BORGES MC, HORTA BL, et al. Inflammatory Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study. JAMA Psychiatry. 2017;74(12):1226-1233.
[16] VON ELM E, ALTMABN DG, EGGER M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808.
[17] HAWKER GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120(5):3-6.
[18] BURGESS S, DUDBRIDGE F, THOMPSON SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880-1906.
[19] YANG J, FERREIRA T, MORRIS AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44(4):369-375, S1-3.
[20] BOWDEN J, DAVEY SMITH G, HAYCOCK PC, et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-314.
[21] BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525.
[22] BOWDEN J, DEL GRECO MF, MINELLI C, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783-1802.
[23] BURGESS S, THOMPSON SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-389.
[24] XU J, LI M, GAO Y, et al. Using Mendelian randomization as the cornerstone for causal inference in epidemiology. Environ Sci Pollut Res Int. 2022;29(4):5827-5839.
[25] 刘明,高亚,杨珂璐,等.孟德尔随机化研究的报告规范(STROBE-MR)解读[J].中国循证医学杂志,2022,22(8):978-987.
[26] CLOCKAERTS S, VAN OSCH GJ, BASTIAANSEN-JENNISKENS YM, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis. 2012;71(5):642-647.
[27] HAJ-MIRZAIAN A, MOHAJER B, GUERMAZI A, et al. Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative. Radiology. 2019;293(2):396-404.
[28] GOTO N, OKAZAKI K, AKASAKI Y, et al. Single intra-articular injection of fluvastatin-PLGA microspheres reduces cartilage degradation in rabbits with experimental osteoarthritis. J Orthop Res. 2017;35(11):2465-2475.
[29] BEATTIE MS, LANE NE, HUNG YY, et al. Association of statin use and development and progression of hip osteoarthritis in elderly women. J Rheumatol. 2005;32(1):106-110.
[30] MICHAELSSON K, LOHMANDER LS, TRKIEWICZ A, et al. Association between statin use and consultation or surgery for osteoarthritis of the hip or knee: a pooled analysis of four cohort studies. Osteoarthritis Cartilage. 2017;25(11):1804-1813.
[31] SHAKIBAEI M, JOHN T, SCHULZE-TANZIL G, et al. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol. 2007;73(9):1434-1445.
[32] TANAKA T, MATSUSHITA T, NISHIDA K, et al. Attenuation of osteoarthritis progression in mice following intra-articular administration of simvastatin-conjugated gelatin hydrogel. J Tissue Eng Regen Med. 2019;13(3):423-432.
[33] KLEMENT M, DREXEL H, SAELY CH. Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review. Inflammopharmacology. 2023;31(4):1647-1656.
[34] WU Y, LI X, GUO Y, et al. Pravastatin Reduces Matrix Metalloproteinases Expression and Promotes Cholesterol Efflux in Osteoarthritis Chondrocytes. Evid Based Complement Alternat Med. 2022;2022:9666963.
[35] ABELES AM, PILLINGER MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum. 2006;54(2):393-407.
[36] PATHAK NN, BALAGANUR V, LINGARAJU MC, et al. Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy. Pharmacol Rep. 2015;67(3):513-519.
[37] ZHANG K, JI Y, DAI H, et al. High-Density Lipoprotein Cholesterol and Apolipoprotein A1 in Synovial Fluid: Potential Predictors of Disease Severity of Primary Knee Osteoarthritis. Cartilage. 2021;13:1465S-1473S.
[38] GIERMAN LM, KUHNAST S, KOUDIJS A, et al. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis. Ann Rheum Dis. 2014;73(5):921-927.
|